- Home
- NGD vs AKRO Comparison
NGD vs AKRO Comparison
Compare NGD & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGD
- AKRO
- Stock Information
- Founded
- NGD N/A
- AKRO 2017
- Country
- NGD Canada
- AKRO United States
- Employees
- NGD N/A
- AKRO N/A
- Industry
- NGD
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- NGD
- AKRO Health Care
- Exchange
- NGD Nasdaq
- AKRO Nasdaq
- Market Cap
- NGD 2.5B
- AKRO 2.8B
- IPO Year
- NGD 2004
- AKRO 2019
- Fundamental
- Price
- NGD $3.67
- AKRO $37.85
- Analyst Decision
- NGD Buy
- AKRO Strong Buy
- Analyst Count
- NGD 3
- AKRO 9
- Target Price
- NGD $3.88
- AKRO $76.29
- AVG Volume (30 Days)
- NGD 22.8M
- AKRO 1.3M
- Earning Date
- NGD 04-29-2025
- AKRO 05-09-2025
- Dividend Yield
- NGD N/A
- AKRO N/A
- EPS Growth
- NGD N/A
- AKRO N/A
- EPS
- NGD 0.14
- AKRO N/A
- Revenue
- NGD $924,500,000.00
- AKRO N/A
- Revenue This Year
- NGD $25.37
- AKRO N/A
- Revenue Next Year
- NGD $42.62
- AKRO N/A
- P/E Ratio
- NGD $26.69
- AKRO N/A
- Revenue Growth
- NGD 17.55
- AKRO N/A
- 52 Week Low
- NGD $1.66
- AKRO $17.86
- 52 Week High
- NGD $3.86
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- NGD 64.57
- AKRO 44.24
- Support Level
- NGD $3.46
- AKRO $36.46
- Resistance Level
- NGD $3.66
- AKRO $39.13
- Average True Range (ATR)
- NGD 0.24
- AKRO 3.02
- MACD
- NGD 0.02
- AKRO 0.08
- Stochastic Oscillator
- NGD 88.54
- AKRO 59.55
About NGD New Gold Inc.
New Gold Inc participates in the development and operation of intermediate mining properties. The company has a portfolio of two primary assets which are also its operating segments: the Rainy River Mine and the New Afton Mine in Canada. The company also owns the Cerro San Pedro Mine in Mexico. The company derives revenue from the sale of gold, copper, and silver.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.